Research Topics
Species | Phyllis J GoodmanSummaryAffiliation: Fred Hutchinson Cancer Research Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Moving a randomized clinical trial into an observational cohortPhyllis J Goodman
SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Clin Trials 10:131-42. 2013....
Implementation of the Prostate Cancer Prevention Trial (PCPT)Phyllis J Goodman
Southwest Oncology Group Statistical Center, M S M3 C102, 1100 Fairview Avenue North, Box 19024, Seattle, WA 98109 1024, USA
Control Clin Trials 25:203-22. 2004..We present an overview of the study design, details of the administrative structure of the study and a description of the successful implementation of the accrual phase...
Transition of a clinical trial into translational research: the prostate cancer prevention trial experiencePhyllis J Goodman
Fred Hutchinson Cancer Research Center, Seattle WA 98109, USA
Cancer Prev Res (Phila) 3:1523-33. 2010..We provide a framework for doing collaborative research in an international setting structured around a common theme of a clinical trial...- The prostate cancer prevention trial: design, biases and interpretation of study resultsPhyllis J Goodman
Southwest Oncology Group Statistical Center, Seattle, Washington 98109 1024, USA
J Urol 175:2234-42. 2006..We describe the complexities of the study design of the PCPT and how they influenced the end point chosen, trial implementation, analysis and interpretation of the results... - Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approachMary W Redman
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
Cancer Prev Res (Phila) 1:174-81. 2008..Therefore, men undergoing regular prostate cancer screening or who express an interest in cancer prevention should be informed of the opportunity to take finasteride for preventing prostate cancer... - Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trialMarian L Neuhouser
Cancer Prevention Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Prostate 68:1477-86. 2008.... - Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trialZhihong Gong
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North M4 B402, Seattle, WA 98109 1024, USA
Cancer Epidemiol Biomarkers Prev 15:1977-83. 2006..Obesity increases the risk of high-grade but decreases the risk of low-grade prostate cancer, and this relationship is independent of the lower risk for prostate cancer among men with diabetes... - Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trialAlan R Kristal
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M4 B402, PO Box 19024, Seattle, WA 98109 1024, USA
Am J Epidemiol 168:1416-24. 2008..Genetic or environmental factors that affect the activity of 5-alpha-reductase may be important in the development of symptomatic BPH... - Associations of serum sex steroid hormone and 5α-androstane-3α,17β-diol glucuronide concentrations with prostate cancer risk among men treated with finasterideAlan R Kristal
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
Cancer Epidemiol Biomarkers Prev 21:1823-32. 2012..It also modestly increases serum testosterone (T), estrone (E(1)), and estradiol (E(2)). In this altered hormonal milieu, it is unknown whether serum concentrations of these hormones are associated with prostate cancer risk... - Estimated impact of the Prostate Cancer Prevention Trial on population mortalityJoseph M Unger
Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Cancer 103:1375-80. 2005..The potential detrimental effects of an increased rate of patients who have prostate cancer with high-grade Gleason scores would be outweighed by a reduction in incidence... - Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trialMarian L Neuhouser
Cancer Prevention Program, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M4 B402, Seattle, WA 98019
Cancer Prev Res (Phila) 6:91-9. 2013..Cancer Prev Res; 6(2); 91-9. ©2013 AACR... - Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trialRuth D Etzioni
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
J Urol 174:877-81. 2005..We estimated the long-term effects of finasteride on PSA in men with and without a prostate cancer diagnosis at the end of the study... - Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increaseAlan R Kristal
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Cancer 106:320-8. 2006..The objective of this study was to examine whether demographic and lifestyle characteristics are associated with prostate-specific antigen (PSA) levels and the rate of PSA increase (PSA velocity)... - Biomarker-based methods for determining noncompliance in a prevention trialDonna K Pauler
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Control Clin Trials 23:675-85. 2002..Our results indicate that simple absolute threshold monitoring rules perform just as well as more complicated rules that utilize the entire biomarker history... - Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trialsCatherine M Tangen
Southwest Oncology Group Statistical Center, Seattle, Washington, USA
J Urol 171:S64-7. 2004..We briefly describe the purpose of phase II studies as a source of preliminary data for phase III prevention trials, and address statistical and other practical considerations for phase III prostate cancer prevention trials... - Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisitedEric A Klein
Section of Urologic Oncology, Glickman Urological Institute, Cleveland, OH 44195, USA
J Clin Oncol 23:7460-6. 2005.... - SELECT: the selenium and vitamin E cancer prevention trialEric A Klein
Section of Urologic Oncology, Department of Urology, Cleveland Clinic Foundation, Cleveland, OH, USA
Urol Oncol 21:59-65. 2003..SELECT is a randomized, prospective, double-blind study designed to determine if selenium and vitamin E can reduce the risk of prostate cancer among healthy men... - The selenium and vitamin E cancer prevention trialEric A Klein
Section of Urologic Oncology, Urological Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, OH 44195, Cleveland, USA
World J Urol 21:21-7. 2003.... - The influence of finasteride on the development of prostate cancerIan M Thompson
University of Texas Health Science Center, San Antonio, USA
N Engl J Med 349:215-24. 2003.... - Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliterIan M Thompson
Division of Urology, Department of Surgery, University of Texas Health Science Center at San Antonio, San Antonio, Tex, USA
N Engl J Med 350:2239-46. 2004..1 to 4.0 ng per milliliter. CONCLUSIONS: Biopsy-detected prostate cancer, including high-grade cancers, is not rare among men with PSA levels of 4.0 ng per milliliter or less--levels generally thought to be in the normal range... - Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)Scott M Lippman
The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
J Natl Cancer Inst 97:94-102. 2005.... - Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention TrialM Scott Lucia
Department of Pathology, University of Colorado Denver and Health Sciences Center, 4200 E Ninth Ave, Box B 216, Denver, CO 80262, USA
J Natl Cancer Inst 99:1375-83. 2007..We assessed whether the increased high-grade prostate cancer associated with finasteride in the PCPT was due to finasteride's potential effects on tumor morphology or prostate size... - Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention TrialIan M Thompson
Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
J Clin Oncol 25:3076-81. 2007..Using data from men in the finasteride group of the Prostate Cancer Prevention Trial (PCPT), we evaluated the impact of prostate-specific antigen (PSA) and other risk factors on the risk of prostate cancer... - Finasteride improves the sensitivity of digital rectal examination for prostate cancer detectionIan M Thompson
Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
J Urol 177:1749-52. 2007..In the current study we report the impact of finasteride on digital rectal examination sensitivity and specificity... - Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lowerIan M Thompson
Department of Urology, University of Texas Health Science Center at San Antonio, TX 78229, USA
JAMA 294:66-70. 2005..Three fourths of US men older than 50 years have been screened with prostate-specific antigen (PSA) for prostate cancer... - Effect of finasteride on the sensitivity of PSA for detecting prostate cancerIan M Thompson
Department of Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
J Natl Cancer Inst 98:1128-33. 2006..We examined the impact of finasteride on the sensitivity and area under the receiver operating characteristic curve (AUC) of prostate-specific antigen (PSA) for detecting prostate cancer... - Assessing prostate cancer risk: results from the Prostate Cancer Prevention TrialIan M Thompson
Department of Urology, University of Texas Health Science Center, San Antonio, TX 78229, USA
J Natl Cancer Inst 98:529-34. 2006..We used prostate biopsy data from men who participated in the Prostate Cancer Prevention Trial (PCPT) to develop a predictive model of prostate cancer...